FDA
-
-
-
-
-
-
-
InnoCare Releases 2023 Interim Results and Business Highlights
-
-
-
-
-
-
-
InnoCare Announces Approval to Conduct a Phase II Clinical Trial of Orelabrutinib in Combination with Tafasitamab + Lenalidomide in China
-
-
-
-
-
-
-
InnoCare Announces First Prescription of Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma Under Boao Hope City’s Early Access Program
-
-
-
-
-
-
-
InnoCare Announces Inclusion of Orelabrutinib in China National Reimbursement Drug List
-
-
-
-
-
-
-
InnoCare Announces Orphan Drug Designation of Gunagrabtinib by US FDA for Treatment of Cholangiocarcinoma
-
-
-
-
251,762 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All